***Letter of Medical Necessity***

*Date: Month, Day, Year*

TO: *Insurance Company*

FROM: *Physician Name*

SUBJECT: Request for coverage and/ reimbursement for IMPACT® PEPTIDE 1.5 complete peptide-based nutritional formula for immune support.

I am requesting insurance coverage and reimbursement on behalf of my patient, *Name/Date of Birth****.***I have prescribed IMPACT® PEPTIDE 1.5 formula for the dietary management of *Diagnosis or Condition.*

*Verify medical necessity for formula, including:*

* *Diagnoses*
* *BMI*
* *Weight history*
* *Brief documentation of intolerance*
* *Brief documentation of wounds and/or risk of infection*
* *Nutrition prescription*

IMPACT® PEPTIDE 1.5 formula is a nutritionally complete peptide-based formula for immune support. This product is intended for the following nutritional applications:

* Patients at risk of infection associated with major surgery or critical illness
* Patients at risk of GI intolerance due to critical illness or GI disease
* Patients undergoing major elective surgery (upper GI, lower GI, head and neck, cardiac, bladder, gynecologic oncology)1-3
* Patients with trauma, burns, wounds, Stage 3, 4 and unstageable pressure injury4-6
* Patients with volume sensitivity
* Patients with increased caloric needs
* Patients transitioning from total parenteral nutrition

**The product is designed for use as a complete tube feeding. IMPACT® PEPTIDE 1.5** **formula is a medical food intended for use under the supervision of a medical professional.**

|  |  |
| --- | --- |
| **IMPACT**® **PEPTIDE 1.5** | **Attributes of IMPACT**® **PEPTIDE 1.5** |
| **Evidence-based blend of arginine, omega-3 fatty acids from fish oil and nucleotides** | * This immunonutrient blend is supported by multiple clinical studies demonstrating a reduction in the risk of infectious complications after surgery.1-3
* Nutritional wound management shown to be more effective in humans with intakes of 17-25 grams of arginine per day.7,8
* Omega-3 fatty acids modulate cytokines to produce less inflammatory mediators9 and dietary nucleotides support replication of the rapidly dividing cells of the immune system.10
 |
| **Peptide-based** | * Peptides have been shown to promote better nitrogen absorption and utilization compared to whole protein.11,12
* Use of small peptide formulations in the patient with persistent diarrhea, suspected malabsorption or lack of response to fiber is suggested.13
 |
| **MCT:LCT = 50:50**Fat sources: MCT oil, refined fish oil, soybean oil  | * 50% of fat derived from MCT to support absorption and tolerance**.**
 |
| **Macronutrient and micronutrient profile designed to support wound management4** | * High protein (25%)
* Contains increased amounts of vitamin C, selenium and zinc in comparison to standard tube feedings.
 |
| Availability: * 250 mL **cartons** and1000 mL **UltraPak® System bags**
 | * Nestlé products are available in packaging made without the use of BPA.
* UltraPak**®** closed system comes standard with SpikeRight**®** PLUS port to help decrease the risk of contamination and tubing misconnections.14
 |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Name** | **Flavor** | **Case UPC** | **Packaging** | **Calories per each** | **Reimbursement/ NDC Formatted Number** | **HCPCS Code** |
| **IMPACT**® **PEPTIDE 1.5** | Unflavored | 10043900974009 | 24 x 250 mL cartons | 375 | 43900-0973-99 | B4153 |
| **IMPACT**® **PEPTIDE 1.5** | Unflavored | 10043900973712 | 6 x 1000 mL bags | 1500 | 43900-0973-70 | B4153 |

Thank you for taking the time to review this request. Please contact me should you require any additional information.

Sincerely,

*Signature:*

*Name:*

*Title:*

Attachments: *If relevant, include pertinent information supporting evidence of medical necessity and product information. Please refer to* [*www.NestleHealthScience.us*](http://www.NestleHealthScience.us) *for product information.*

REFERENCES:

1. Drover JW et al. Perioperative Use of Arginine-supplemented Diets: A Systematic Review of the Evidence. J Am Coll Surg 2011;212(3):385-399.
2. Chapman JS et al. Post-operative enteral immunonutrition for gynecologic oncology patients undergoing laparotomy decrease wound complications, Gyn Onc 2015;137:523-528.
3. Bertrand J et al. Impact of preoperative immunonutrition on morbidity following cystectomy for bladder cancer: A case-control pilot study . World J Urol 2014; 32:233-237.
4. Posthauer ME et al. The role of nutrition for pressure ulcer management: National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel, and Pan Pacific Pressure Injury Alliance white paper. Wound Care J 2015;28(4):175-188.
5. National Pressure Ulcer Advisory Panel Press Release; April 13, 2016: Washington D.C.
6. Farber MS et al. Reducing costs and patient morbidity in the enterally fed intensive care unit patient. JPEN 2005;29(1 Suppl):S62-S69.
7. Barbul A, Lazarou SA, Efron DT et al. Arginine enhances wound healing and lymphocyte immune responses in humans. Surgery 1990;108:331-337.
8. Chow O and Barbul A. Immunonutrition: Role in wound healing and tissue regeneration. Adv Wound Care 2014;3(1):46-53.
9. Calder PC. Polyunsaturated fatty acids and inflammation. Prostaglandins, Leukotrienes and Essential Fatty Acids 2006;75:197-202.
10. Hess JR and Greenberg NA. The role of nucleotides in the immune and gastrointestinal systems: Potential clinical applications. NCP 2012;27(2):281-294.
11. Meredith JW et al. Visceral protein levels in trauma patients are greater with peptide diet than with intact protein diet. J of Trauma 1990;30(7):S25-S29.
12. Ziegler F et al. Efficiency of enteral nutrition support in surgical patients: Small peptides *v* non-degraded proteins. Gut 1990;31 (11): 1277-1283.
13. McClave SA et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society of Parenteral and Enteral Nutrition (A.S.P.E.N.) JPEN 2016;40(2):159-211.
14. A.S.P.E.N. Enteral practice recommendations. JPEN 2009;33(2):122-167.

|  |
| --- |
|  |
|  |
|  |
|  |
|  |
|  |